Surrozen, Inc. (NASDAQ:SRZN) Given Average Recommendation of “Moderate Buy” by Brokerages

Shares of Surrozen, Inc. (NASDAQ:SRZN) have been given an average recommendation of “Moderate Buy” by the six analysts that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company. The average 1-year price objective among brokers that have updated their coverage on the stock in the last year is $42.00.

Several equities analysts have commented on the stock. Weiss Ratings reissued a “sell (d-)” rating on shares of Surrozen in a research report on Friday, July 17th. HC Wainwright reaffirmed a “buy” rating and set a $44.00 price objective (up from $36.00) on shares of Surrozen in a research report on Thursday, May 7th. TD Cowen started coverage on Surrozen in a research note on Tuesday, April 21st. They issued a “buy” rating on the stock. Finally, Zacks Research upgraded Surrozen from a “strong sell” rating to a “hold” rating in a report on Tuesday.

Surrozen Stock Performance

Shares of SRZN opened at $19.20 on Thursday. The company’s 50-day simple moving average is $23.44 and its 200-day simple moving average is $25.28. Surrozen has a 1 year low of $8.70 and a 1 year high of $35.00. The stock has a market capitalization of $222.91 million, a PE ratio of -0.51 and a beta of 0.51.

Surrozen (NASDAQ:SRZN) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($11.65) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.09) by ($10.56). The company had revenue of $5.00 million for the quarter, compared to analysts’ expectations of $4.00 million. On average, sell-side analysts predict that Surrozen will post -7.2 earnings per share for the current year.

Insider Buying and Selling

In other Surrozen news, CEO Craig C. Parker sold 4,524 shares of the stock in a transaction dated Monday, May 4th. The stock was sold at an average price of $33.33, for a total value of $150,784.92. Following the sale, the chief executive officer owned 16,553 shares of the company’s stock, valued at $551,711.49. This trade represents a 21.46% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, COO Charles O. Williams sold 2,036 shares of Surrozen stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $33.33, for a total value of $67,859.88. Following the completion of the transaction, the chief operating officer owned 16,571 shares of the company’s stock, valued at $552,311.43. The trade was a 10.94% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 333,144 shares of company stock worth $7,177,690 over the last 90 days. 31.74% of the stock is currently owned by company insiders.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. China Universal Asset Management Co. Ltd. grew its holdings in Surrozen by 50.0% during the 4th quarter. China Universal Asset Management Co. Ltd. now owns 1,500 shares of the company’s stock worth $34,000 after acquiring an additional 500 shares in the last quarter. Citadel Advisors LLC raised its holdings in shares of Surrozen by 32.8% in the 3rd quarter. Citadel Advisors LLC now owns 13,875 shares of the company’s stock valued at $179,000 after purchasing an additional 3,424 shares in the last quarter. Persistent Asset Partners Ltd acquired a new stake in shares of Surrozen in the 4th quarter valued at $99,000. Schonfeld Strategic Advisors LLC lifted its position in shares of Surrozen by 8.1% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 74,645 shares of the company’s stock worth $1,687,000 after purchasing an additional 5,621 shares during the last quarter. Finally, Geode Capital Management LLC lifted its position in shares of Surrozen by 22.6% during the 2nd quarter. Geode Capital Management LLC now owns 30,963 shares of the company’s stock worth $277,000 after purchasing an additional 5,702 shares during the last quarter. Hedge funds and other institutional investors own 66.57% of the company’s stock.

About Surrozen

Surrozen, Inc is a clinical-stage biopharmaceutical company focused on developing novel therapeutic antibodies that target the Wnt signaling pathway for applications in tissue repair, regeneration and oncology. Founded in 2012 and headquartered in South San Francisco, California, the company leverages its proprietary SurroBody platform to design bispecific antibody molecules capable of modulating Wnt receptor activity with enhanced tissue specificity.

The SurroBody platform enables the generation of high-affinity, dual-binding antibodies engineered to either activate or inhibit Wnt signaling, a pathway critical to cell proliferation, differentiation and homeostasis.